PSA Test: When to Order, What Results Mean, and How to Act on Them

What PSA Actually Measures

PSA is a serine protease enzyme produced almost exclusively by prostatic epithelial cells, and its primary biological function is liquefying semen after ejaculation. Small amounts leak into the bloodstream, where they can be measured with a standard immunoassay. The test does not diagnose cancer. It flags the possibility that something in the prostate, whether benign enlargement, infection, or malignancy, is releasing more protein than expected 1.

The U.S. Food and Drug Administration first approved the PSA assay in 1986 as a monitoring tool for men already diagnosed with prostate cancer. Screening use followed in the early 1990s. Since then, the test has been one of the most debated laboratory markers in medicine, praised for catching aggressive cancers early and criticized for triggering biopsies that find indolent disease 2. A single PSA number, taken out of context, tells you very little. Combined with age, family history, digital rectal exam findings, and PSA kinetics over time, it becomes a genuinely useful clinical signal.

PSA circulates in two forms: bound to proteins (complexed PSA) and free. The ratio of free to total PSA helps distinguish benign prostatic hyperplasia (BPH) from cancer. Men with BPH tend to have a higher percentage of free PSA. A free PSA fraction below 10% raises the probability of cancer significantly, while a fraction above 25% makes cancer less likely 3.

When to Order a PSA Test

The right time to order a PSA depends on why you are ordering it. Screening, TRT monitoring, and symptom-driven evaluation each follow different timelines.

For prostate cancer screening, the USPSTF issued a Grade C recommendation in 2018: men aged 55 to 69 should make an individual decision about PSA-based screening after discussing the potential benefits and harms with their clinician 4. The task force recommended against routine screening in men aged 70 and older (Grade D). The American Urological Association (AUA) suggests a baseline PSA at age 40 to 45 for men at average risk, with rescreening intervals of 2 to 4 years depending on that initial value 5.

For testosterone replacement therapy, the 2018 Endocrine Society Clinical Practice Guideline is specific: obtain a baseline PSA before initiating testosterone, recheck at 3 to 6 months, and then test annually 6. If PSA rises by more than 1.4 ng/mL within any 12-month period during TRT, or if the absolute value exceeds 4.0 ng/mL, referral to urology is warranted. The guideline also recommends against starting TRT in men with a PSA above 4.0 ng/mL (or above 3.0 ng/mL in high-risk men) without urological evaluation first.

For symptom evaluation, order a PSA when a patient presents with lower urinary tract symptoms (hesitancy, nocturia, weak stream), hematuria of unclear origin, or pelvic pain suggestive of prostatitis. A PSA drawn during acute urinary retention or within 48 hours of ejaculation, vigorous cycling, or a digital rectal exam may be falsely elevated. Wait at least 48 hours after any of these events before drawing the sample 7.

Normal PSA Ranges by Age

There is no single "normal" PSA. The concept of age-adjusted reference ranges, first proposed by Oesterling in 1993, acknowledges that the prostate grows with age and produces more PSA even in the absence of malignancy 8.

Commonly cited age-specific cutoffs are:

• Age 40 to 49: 0 to 2.5 ng/mL
• Age 50 to 59: 0 to 3.5 ng/mL
• Age 60 to 69: 0 to 4.5 ng/mL
• Age 70 to 79: 0 to 6.5 ng/mL

These thresholds are guidelines, not guarantees. The Prostate Cancer Prevention Trial (PCPT) demonstrated that 15.2% of men with a PSA at or below 4.0 ng/mL still had prostate cancer on biopsy, and 14.9% of those cancers were high-grade (Gleason 7 or above) 9. A PSA of 3.1 ng/mL in a 45-year-old man warrants more concern than the same value in a 72-year-old.

Dr. William Catalona, who pioneered PSA-based screening, has noted: "PSA is not a perfect test, but it is the best early detection tool we have. The key is interpreting it in context, not relying on a single threshold" 10.

What a High PSA Means (and What It Does Not)

An elevated PSA is not a cancer diagnosis. Four common causes drive PSA above reference range, and only one of them is malignancy.

Benign prostatic hyperplasia (BPH) is the most frequent cause. A prostate that weighs 60 grams will produce roughly twice the PSA of a 30-gram gland simply because there is more secretory tissue. BPH typically produces PSA in the 4.0 to 10.0 ng/mL range, and free PSA percentage tends to be above 25% 3.

Prostatitis, both bacterial and non-bacterial, can spike PSA dramatically. Acute bacterial prostatitis may push PSA above 20 ng/mL. After antibiotic treatment, levels usually normalize within 6 to 8 weeks, at which point a repeat draw gives a more accurate baseline 11.

Recent mechanical stimulation of the prostate (catheterization, biopsy, vigorous cycling, ejaculation within 48 hours) can transiently raise PSA. These are pre-analytical confounders, not pathology.

Prostate cancer is the diagnosis everyone fears. In the European Randomized Study of Screening for Prostate Cancer (ERSPC), PSA-based screening reduced prostate cancer mortality by 20% over 16 years of follow-up (rate ratio 0.80, 95% CI 0.72 to 0.89), but at the cost of substantial overdiagnosis 12. The USPSTF weighed this trade-off in its 2018 recommendation, concluding that the net benefit is small and depends on patient preferences.

When PSA falls in the "gray zone" of 4.0 to 10.0 ng/mL, additional tools can sharpen diagnostic accuracy. The Prostate Health Index (PHI) combines total PSA, free PSA, and [-2]proPSA into a single score. The 4Kscore adds human kallikrein 2. Both reduce unnecessary biopsies by 20% to 30% compared with PSA alone 13.

What a Low PSA Means

A very low PSA (below 1.0 ng/mL) in a man aged 50 to 60 is reassuring. The ERSPC data show that men with a PSA below 1.0 ng/mL at age 60 have a very low lifetime risk of prostate cancer mortality, and some guidelines suggest these men can safely extend their rescreening interval to every 5 years or discontinue screening altogether 12.

An unexpectedly low PSA can also signal the use of 5-alpha reductase inhibitors (5-ARIs). Both finasteride and dutasteride suppress PSA by approximately 50% within 6 months of starting treatment 14. If a man is on finasteride and his reported PSA is 2.0 ng/mL, the clinically relevant number is effectively 4.0 ng/mL. Failing to double the PSA in 5-ARI users is a well-documented source of missed diagnoses. Any PSA interpretation in a man taking finasteride or dutasteride must use the "multiply by two" correction.

Hypogonadal men (total testosterone below 300 ng/dL) also tend to have lower baseline PSA values. This is relevant because initiating TRT in these men typically raises PSA by 0.3 to 0.5 ng/mL in the first 6 to 12 months as testosterone stimulates normal prostatic tissue 6. This modest rise is expected. Only a rise exceeding 1.4 ng/mL in 12 months or crossing the 4.0 ng/mL threshold should trigger urological referral.

How Testosterone Therapy Affects PSA

The relationship between testosterone and PSA has been studied extensively, and the data are more reassuring than many patients expect.

A 2016 meta-analysis of 22 randomized controlled trials (N = 2,351) found that testosterone therapy increased PSA by a mean of 0.31 ng/mL compared with placebo over treatment periods ranging from 3 to 36 months 15. That is a statistically detectable but clinically modest effect. The same analysis found no significant increase in prostate cancer incidence among testosterone-treated men.

The 2018 Endocrine Society guideline states: "The evidence does not support the notion that testosterone therapy increases the risk of prostate cancer or converts subclinical cancer to clinically significant disease" 6. The guideline still mandates monitoring because surveillance, not avoidance, is the appropriate response to theoretical risk in a YMYL clinical domain.

Monitoring protocol during TRT:

1. Baseline PSA before first injection or application
2. Repeat PSA at 3 to 6 months
3. Annual PSA thereafter
4. Refer to urology if PSA exceeds 4.0 ng/mL, rises by more than 1.4 ng/mL in 12 months, or if digital rectal exam is abnormal

Men on TRT who also take finasteride (sometimes prescribed for hair loss or BPH) need both corrections applied: double the lab-reported PSA, then interpret the corrected value against expected TRT-related increases.

Factors That Can Raise or Lower PSA

Beyond the major clinical conditions, several medications, activities, and biological variables shift PSA levels.

Factors that raise PSA:

• Acute urinary tract infection or prostatitis 11
• Urinary retention or catheterization
• Ejaculation within 24 to 48 hours of the blood draw
• Extended cycling (more than 30 minutes on a narrow saddle)
• Testosterone replacement therapy (mean increase approximately 0.3 ng/mL) 15
• Obesity paradoxically lowers PSA through hemodilution, but visceral fat may increase prostatic inflammation. The net effect depends on BMI range.

Factors that lower PSA:

• 5-alpha reductase inhibitors (finasteride, dutasteride): approximately 50% reduction at 6 months 14
• Statins: a 2008 study in the Journal of the National Cancer Institute reported that statin users had PSA values 4.1% lower than non-users (P <0.001) 16
• Thiazide diuretics: modest reduction observed in some cohorts
• Obesity (hemodilution effect): higher blood volume dilutes the circulating PSA concentration

Understanding these modifiers prevents both false alarm and false reassurance. A man on dutasteride, rosuvastatin, and hydrochlorothiazide could have three independent PSA-lowering effects masking a clinically significant rise.

PSA Velocity and PSA Density

Two derived metrics add diagnostic power beyond the absolute PSA number.

PSA velocity measures the rate of change over time. A rise of more than 0.75 ng/mL per year is associated with higher prostate cancer risk, even when the absolute PSA remains below 4.0 ng/mL. Carter et al. demonstrated that men who later developed lethal prostate cancer had measurably steeper PSA slopes 10 to 15 years before diagnosis compared with men who developed indolent disease 17. Tracking velocity requires at least two PSA measurements separated by 12 to 24 months. This is why annual testing during TRT is not optional.

PSA density divides the total PSA by prostate volume (measured by transrectal ultrasound or MRI). A density above 0.15 ng/mL per gram of tissue suggests that the PSA elevation is disproportionate to prostate size and raises suspicion for cancer. A density below 0.10 ng/mL per gram in a man with a mildly elevated PSA and a large prostate (above 50 grams) is consistent with BPH alone.

The AUA recommends incorporating PSA density and velocity into the decision to biopsy, particularly in the gray zone of 4.0 to 10.0 ng/mL, where roughly 75% of biopsies return benign results 5.

How to Prepare for a PSA Test

Preparation is minimal. No fasting is required. Avoid the following for at least 48 hours before the draw: ejaculation, vigorous exercise involving the perineum (cycling, horseback riding), and any urological procedure. If you are being treated for prostatitis, wait at least 6 weeks after completing antibiotics before using the result as a new baseline 7.

Tell your clinician about all medications. Finasteride, dutasteride, and some herbal supplements (notably saw palmetto at high doses) may alter the result. Provide your most recent PSA value so the clinician can calculate velocity.

The blood draw itself takes under 5 minutes. A standard serum separator tube is collected from any peripheral vein. Results are reported in ng/mL.

When to Repeat and When to Refer

A single elevated PSA is not an indication for biopsy. Repeat the test in 4 to 6 weeks under controlled conditions (no recent ejaculation, no cycling, no active infection) before making clinical decisions. If the repeat confirms elevation, the next steps follow a structured algorithm.

The NCCN early detection framework recommends considering multiparametric MRI of the prostate (mpMRI) before biopsy for men with PSA in the 4.0 to 10.0 ng/mL range. A PI-RADS score of 1 or 2 on mpMRI has a negative predictive value exceeding 90% for clinically significant cancer, which may allow the patient to defer biopsy and instead undergo active surveillance with serial PSA and repeat imaging 18.

Dr. Peter Carroll, former chair of urology at UCSF, has stated: "MRI-targeted biopsy detects more clinically significant cancers and fewer insignificant ones than systematic biopsy. It should be the standard pathway for any man with an elevated PSA" 18.

Refer to urology when: PSA exceeds 4.0 ng/mL on repeat testing, PSA velocity exceeds 0.75 ng/mL per year, digital rectal exam reveals a nodule or asymmetry, or PSA rises by more than 1.4 ng/mL in 12 months during TRT. Early referral is not the same as early biopsy. It is a conversation with a specialist who has the full toolset (mpMRI, PHI, 4Kscore, genetic risk panels) to guide the next step.